ImmunoACT
- ImmunoACT, supported by IIT-Bombay and Laurus Labs, has received approval from the Central Drugs Standard Control Organization (CDSCO) for India's first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel), designed for the treatment of relapsed/refractory (r/r) B-cell lymphomas and leukemia.
- NexCAR19 is a humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy, the first of its kind to be developed in India, representing a significant advancement in cell-and-gene therapies.
- Laurus Labs, a pharmaceutical company, invested over $18 million in ImmunoACT to support its research and development, aiming to make CAR-T therapy accessible and affordable in India and other resource-constrained settings.
- The approval of ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
News Snippets
- 1 India-Bhutan Hold Talks on Boundary and Cooperation
- 2 New Species of Congrid Eel Discovered
- 3 Delhi Becomes the 28th Legislature to Join NeVA
- 4 U.S. Withdraws from U.N. Climate Damage Fund Board
- 5 India and Vietnam Hold Fourth Policy Planning Dialogue
- 6 US Targets India’s High Tariffs
- 7 India and Armenia Sign MoU on Medical Product Regulation
- 8 Poland & Baltic States to Withdraw from Ottawa Convention
- 9 India and Mongolia Strengthen Strategic Partnership
- 10 New Freshwater Algae Species Discovered in Western Ghats